Department of Laboratory Medicine, Catholic University, Rome, Italy.
Proteomics Clin Appl. 2010 Feb;4(2):143-58. doi: 10.1002/prca.200900157. Epub 2009 Dec 2.
Most cancer cells exhibit elevated levels of glycolysis and this metabolic pathway seems to be related to a greater glucose uptake. This phenomenon, known as the Warburg effect, is considered one of the most fundamental metabolic alterations during malignant transformation. Originally, Warburg hypothesised that the aerobic glycolysis of cancer cells could be just an aspect of a more complex metabolic adaptation. However, this intriguing discovery was partially misinterpreted and disregarded over time. In recent years, the peculiarities of cancer cell metabolism have been re-evaluated in light of new metabolic data that seem to confirm and to widen the original concept of the Warburg effect. In fact, biochemical, molecular, and, above all, proteomic studies on the multifaceted roles of glycolytic enzymes in cancer cells in general, and in cancer stem cells in particular, seem to suggest more complex functional adaptations. These adaptations result in significantly altered protein expression patterns, and they have fundamental implications for diagnosis, prognosis and therapy. Revisiting the Warburg effect in cancer cells with a proteomic approach could deepen our knowledge of cancer cell metabolism and of cancer cell biology in general. Moreover, by identifying useful diagnostic, prognostic and therapeutic targets, it could significantly impact clinical practice.
大多数癌细胞表现出高水平的糖酵解,这种代谢途径似乎与更高的葡萄糖摄取有关。这种现象被称为沃伯格效应,被认为是恶性转化过程中最基本的代谢改变之一。最初,沃伯格假设癌细胞的有氧糖酵解可能只是更复杂代谢适应的一个方面。然而,随着时间的推移,这个有趣的发现被部分误解和忽视。近年来,随着新的代谢数据的出现,重新评估了癌细胞代谢的特殊性,这些数据似乎证实并拓宽了沃伯格效应的原始概念。事实上,关于糖酵解酶在癌细胞中的多方面作用的生化、分子,尤其是蛋白质组学研究,似乎表明了更复杂的功能适应。这些适应导致蛋白质表达模式的显著改变,对诊断、预后和治疗具有重要意义。通过蛋白质组学方法重新审视癌细胞中的沃伯格效应,可以加深我们对癌细胞代谢和一般癌细胞生物学的认识。此外,通过确定有用的诊断、预后和治疗靶点,它可以对临床实践产生重大影响。
Expert Rev Proteomics. 2011-8
Cancer Lett. 2009-4-18
Semin Cancer Biol. 2009-2
Cancer Res. 2007-2-15
Mol Aspects Med. 2009-12-6
Front Oncol. 2022-5-5
RSC Med Chem. 2020-12-16
Cancers (Basel). 2020-9-30
BMC Pharmacol Toxicol. 2019-5-3
J Oral Maxillofac Pathol. 2016
BMC Med Genomics. 2014
Front Biol (Beijing). 2012-8-1